フチバチニブ
フチバチニブ 物理性質(zhì)
- 沸點(diǎn) :
- 733.8±60.0 °C(Predicted)
- 比重(密度) :
- 1.33±0.1 g/cm3(Predicted)
- 貯蔵溫度 :
- Store at -20°C
- 溶解性:
- DMSO:38.0(Max Conc. mg/mL);90.81(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);71.69(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.38(Max Conc. mM)
Ethanol:0.5(Max Conc. mg/mL);1.19(Max Conc. mM)
- 外見(jiàn) :
- A crystalline solid
- 酸解離定數(shù)(Pka):
- 3.60±0.30(Predicted)
- 色:
- White to yellow
- InChIKey:
- KEIPNCCJPRMIAX-HNNXBMFYSA-N
- SMILES:
- C(N1CC[C@H](N2C3C(C(C#CC4=CC(OC)=CC(OC)=C4)=N2)=C(N)N=CN=3)C1)(=O)C=C
安全性情報(bào)
- リスクと安全性に関する聲明
- 危険有害性情報(bào)のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語(yǔ) |
警告 |
| 危険有害性情報(bào) |
| コード |
危険有害性情報(bào) |
危険有害性クラス |
區(qū)分 |
注意喚起語(yǔ) |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
強(qiáng)い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
呼吸器への刺激のおそれ |
特定標(biāo)的臓器毒性、単回暴露； 気道刺激性 |
3 |
警告 |
|
|
|
| 注意書(shū)き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P305+P351+P338 |
眼に入った場(chǎng)合：水で數(shù)分間注意深く洗うこと。次にコ ンタクトレンズを著用していて容易に外せる場(chǎng)合は外す こと。その後も洗浄を続けること。 |
|
フチバチニブ 価格
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購(gòu)入 |
フチバチニブ 化學(xué)特性,用途語(yǔ),生産方法
効能
抗悪性腫瘍薬, 受容體型チロシンキナーゼ阻害薬
使用
Futibatinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.
主な応用
Futibatinib has received accelerated approval in the U.S. for the treatment of patients with advanced solid tumors that carry FGFR gene mutations. In addition, it is approved in the U.S. for the treatment of patients with cholangiocarcinoma whose disease has progressed after prior chemotherapy. The development and approval of Futibatinib provides a new targeted treatment option for cancer patients that carry FGFR mutations, especially for those who are resistant or intolerant to existing treatment options.
brand name
Lytgobi
in vitro
Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR.
in vivo
Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor
effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by
administering at moderate intervals, such as intermittent administration
of every other day dosing and 2 times/week, and reducing the sustained
elevation and weight suppression blood phosphorus level, and take a
antitumor effective as daily administration.
フチバチニブ 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
フチバチニブ 生産企業(yè)
Global( 116)Suppliers
1448169-71-8(フチバチニブ)キーワード:
- 1448169-71-8
- FGFR-IN-1
- FGFR-IN-1;FUTIBATINIB;TAS-120
- FUTIBATINIB;TAS120
- TAS-120 (Futibatinib)
- CS-2681
- CS-2344
- 2-Propen-1-one, 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-
- 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one
- Futibatinib
- (S)-1-(3-(4-Amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one
- 2H6]-Futibatinib
- FGFR,Inhibitor,TAS-120,Futibatinib,Fibroblast growth factor receptor,inhibit,TAS 120
- 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
- Futibatinib Crude
- Bexagliflozin Impurity 14
- Futibatinib, 10 mM in DMSO
- 1-[(3S)-3-[4-Amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one (ACI)
- フチバチニブ
- 1-[(3S)-3-{4-アミノ-3-[2-(3,5-ジメトキシフェニル)エチニル]ピラゾロ[3,4-d]ピリミジン-1-イル}ピロリジン-1-イル]プロパ-2-エン-1-オン
- 1-[(S)-3-[3-[(3,5-ジメトキシフェニル)エチニル]-4-アミノ-1H-ピラゾロ[3,4-d]ピリミジン-1-イル]ピロリジノ]-2-プロペン-1-オン
- 1-[(3S)-3-{4-アミノ-3-[2-(3,5-ジメトキシフェニル)エチニル]-1H-ピラゾロ[3,4-d]ピリミジン-1-イル}ピロリジン-1-イル]プロパ-2-エン-1-オン